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A B S T R A C T
A better characterization of the HIV reservoir is pivotal for the development of eﬀective eradication strategies.
Accurate quantiﬁcation of the latent reservoir remains challenging. Starting from a regular blood draw, the Tat/
Rev induced limiting dilution assay (TILDA) combines serial dilution of CD4+ T cells with a PCR-based detection
of HIV-1 spliced mRNA produced upon cell stimulation. Here we adapted the original protocol for HIV-1 subtype
B to detect tat/rev mRNAs transcribed from reactivated latently infected cells in long term suppressed patients
infected with HIV-1 subtype C. Given the heterogeneity of global HIV epidemiology, it is pivotal to develop
assays with optimal performances also in patients infected with non-B subtypes. We observed that, in these
patients infected with subtype C virus, the HIV reservoir quantiﬁed by TILDA correlates with both the time of
virological suppression and CD4/CD8 ratio.
1. Introduction
The existence of a latent reservoir, constituted by integrated viral
DNA that is replication-competent despite being transcriptionally silent,
represents the main obstacle for HIV eradication (Chun et al., 1997,
1995; Richman et al., 2009). The latent viral reservoir is established
early during the course of infection (Chun et al., 1997, 1995), and al-
lows persistence of HIV even in presence of potent combination anti-
retroviral therapy (cART) that can eﬀectively block viral replication
(Chun et al., 2010; Davey et al., 1999). During prolonged suppressive
cART, cells harboring silent provirus are extremely rare (Eriksson et al.,
2013). Nevertheless, in the absence of viral transcription and virus
production, the immune system is not able to recognize them and
cannot target them for elimination (Rasaiyaah et al., 2013). As a con-
sequence, in patients who interrupt suppressive antiretroviral therapy,
the relatively few latent viruses are reactivated leading to plasma viral
rebound within a few weeks (Chun et al., 2010; Davey et al., 1999).
The growing awareness of the importance of reservoir size assess-
ment for the tailored management of HIV-1 infected patients sets the
need for assays that can accurately quantify the number of cells har-
boring replication-competent virus in vivo. Evidence-based studies en-
rolling elite and post-treatment controllers, i.e. individuals who control
viral replication in absence of antiretroviral therapy, have shown that
the size of the latent reservoir is related to the likelihood of and the time
to viral rebound (Sáez-Cirión et al., 2013; Walker and Yu, 2013).
Consistent with a role of cART in reducing reservoir size and improving
patient survival (Archin et al., 2012; Palella et al., 1998), early start of
treatment is associated with lower levels of proviral DNA and, in turn,
with longer time to rebound and reduced risk of virological failure
(Avettand-Fènoël et al., 2016; Williams et al., 2014; Yerly et al., 2004).
Over the last two decades, diﬀerent methods for reservoir quanti-
ﬁcation have been developed to cope with the low number of cells
harboring replication-competent virus, which challenges standard mo-
lecular techniques. The quantitative viral outgrowth assay (QVOA)
determines the number of resting CD4+ T cells releasing active virus
upon stimulation, and is considered the gold standard to determine
reservoir size in HIV infected patients during cART (Eriksson et al.,
2013). Nevertheless, QVOA is time-consuming and requires a large
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amount of blood (Eriksson et al., 2013; Ho et al., 2013). Quantiﬁcation
of total HIV-1 DNA by means of real-time PCR or digital droplet PCR is
frequently used as an alternative method for reservoir assessment in
clinical studies (Alidjinou et al., 2015). Despite being a relatively simple
technique that can be performed starting from a variety of biological
samples (Avettand-Fènoël et al., 2016; Williams et al., 2014; Yerly
et al., 2004), quantiﬁcation of HIV-1 DNA overestimates the size of the
reservoir as the vast majority of detectable HIV-1 genomes is not re-
plication-competent (Ho et al., 2013). Quantiﬁcation of cell-associated
HIV-1 RNA (CA-HIV RNA) produced upon in vitro stimulation may
represent an additional reservoir biomarker (Pasternak et al., 2013).
However, gag-pol RNA in stimulated cells may be the result of tran-
scription starting from an upstream promoter, revealing the presence of
a defective provirus located into an activated host gene rather than an
actual latent provirus that has been reactivated (Bullen et al., 2014). A
recently developed assay combines a FISH method targeting gag-pol
mRNAs with the detection of p24 protein, improving speciﬁcity and
limiting the issue of false positive events (Baxter et al., 2018, 2017;
Grau-Expósito et al., 2017; Martrus et al., 2016). However, the method
is still in the early phases of development and further investigation is
required to determine its accuracy. Detection of multiply-spliced RNA
(msRNA) molecules has been proposed as an alternative method to
improve speciﬁcity in identifying reactivation of a competent virus, as
spliced viral RNA is frequently missing in defective viruses due to de-
letions that encompass tat and rev genes (Ho et al., 2013). Based on
these observations, Procopio and colleagues established the Tat/rev
Induced Limiting Dilution Assay (TILDA), a PCR-based method that
provides an estimate of the frequency of latently HIV-1 infected CD4+ T
cells producing tat/rev msRNA (Procopio et al., 2015). This assay
couples the sensitivity of a molecular method with a limiting diluting
assay, thereby providing accurate quantiﬁcation of the clinically re-
levant reservoir starting from a regular blood sample.
HIV-1 has an enormous genetic variability that played a crucial role
in its worldwide spread (Hemelaar, 2013, 2012). HIV-1 diversity results
in the presence of groups, subtypes and recombinant forms that sig-
niﬁcantly diﬀer in terms of geographical distribution and pathogenesis
(Hemelaar, 2013, 2012). Changes in nucleotide composition between
diﬀerent subtypes were estimated at around 15 %, although region and
subtype accessed can signiﬁcantly inﬂuence genotypic and phenotypic
diversity (Li et al., 2015). Historically, subtype B has been predominant
in Europe and North America, while subtype C is the most dominant
subtype in Africa. However, in the past decade, as a result of the in-
crease in migratory ﬂows, Europe has seen a remarkable increase in the
number of cases diagnosed with HIV-1 subtype C (Hemelaar et al.,
2019; Lai et al., 2014).
Considering the impact of sequence diversity, changes in subtype
distribution can impact on the performances of molecular methods for
HIV-1 detection. Sequence diﬀerences between subtype B and C point
towards the inability to detect clade C viruses using TILDA, which has
been designed based on subtype B viruses (Procopio et al., 2015). Here
we adapted the TILDA assay to obtain a technique to quantify HIV-1
reservoir size in long-term suppressed patients infected with subtype C.
2. Methods
2.1. Participants and samples
Samples were collected after receiving approval from the Erasmus
MC Medical Ethics Committee and St. Orsola Hospital (489/2018/Sper/
AOUBo) Ethics Committee. All enrolled patients were ≥18 years and
provided written informed consent; patients infected with either sub-
type B or C HIV-1 were cART-treated for at least 2 years at the time of
the study, with undetectable viral load (detection limit of 20 copies/ml
of plasma) for at least one year. PBMCs were collected from blood
samples obtained from HIV-1 infected patients that were referred to the
Infectious diseases Unit of the St. Orsola Hospital or from leukapheresis
obtained from patients that were referred to the Infectious Disease
Section of the Erasmus University Medical Center. PBMCs were isolated
by Ficoll Paque (GE Healthcare) density centrifugation according to the
manufacturer’s instructions. Plasma HIV-RNA load was detected by
standard commercial viral RNA detection assay (COBAS® AMPLICOR,
Roche Molecular Systems, Inc., Branchburg, NJ, USA). CD4+ and CD8+
T lymphocyte count was determined by ﬂow cytometry (FACScan,
Becton & Dickinson, USA) using commercially available monoclonal
antibodies (Perfetto and McCrary, 1999); speciﬁcally, CD4+ T cells
were stained with PE anti-human CD3 antibody (Beckton Dickinson,
cat. No. 7347) and FITC anti-human CD4 (Beckton Dickinson, cat. No.
347413), whereas CD8+ T cells were stained with PE anti-human CD3
antibody (Beckton Dickinson, cat. No. 7347) and FITC anti-human CD8
(Cymbus Biotechnology, cat. No. CBL131 F). Subtype characterization
was determined according to the HIV-1 pol gene sequence (Bon et al.,
2010; Musumeci et al., 2016).
2.2. Quantiﬁcation of total HIV-1 DNA
DNA was puriﬁed from PBMCs (Quick DNA Microprep Kit, Zymo
Research) and quantiﬁed using Nanodrop (Labtech, Ringmer, UK).
Total HIV-1 DNA levels were measured with the HIV-1 DNA qPCR kit
(Diatheva, Fano, Italy) following manufacturer’s instructions. The
number of HIV-1 copies was normalized to the number of CD4+T cells
present in the sample calculated based on the percentage of CD4+ T
cells of the same blood sample (Massanella et al., 2015).
2.3. CD4+ T cells isolation
CD4+ T cells were isolated from PBMCs by negative magnetic se-
lection (EasySep™ Human CD4+ T Cell Isolation Kit, Stemcell
Technologies). Upon isolation, CD4+ T cells were cultured in RPMI
1640 (Euroclone) supplemented with 2 mM L-Glutamine (Euroclone),
10 % Fetal Bovine Serum (Gibco, Life Technologies) and 1 % Penicillin
Streptomycin (Euroclone) for 3 h at 37 °C and 5 % CO2. After 3 h, cells
were stimulated with 100 ng/ml PMA (SigmaAldrich) and 1 μg/ml io-
nomycin (Sigma Aldrich) for 12−16 hours.
2.4. C-TILDA
Subtype C speciﬁc TILDA (C-TILDA) primers and probe were design
based on subtype C alignments available in Los Alamos Database using
WebLogo (https://weblogo.berkeley.edu/logo.cgi). Primers and probes
were designed in the most conserved regions of the tat-rev exons, se-
lecting the more represented nucleotides in the alignment (Table 1,
Supplementary Figure S1).
CD4+ T cells obtained from HIV-1 infected patients were stimulated
overnight with 100 ng/ml PMA and 1 μg/ml ionomycin. After stimu-
lation, cells were counted and serially diluted in culture media to 54 ×
106 cells/ml, 27 × 106 cells/ml, 9 × 106 cells/ml and 3 × 106 cells/
ml. From each serial dilution, 1 μl of the cell suspension was plated in a
96-well plate as described by Procopio and colleagues (Procopio et al.,
2015). 18–24 replicates of each serial dilution were tested. Pre-ampli-
ﬁcation was performed using SuperScript III Platinum One-Step qRT-
Table 1
Sequence of subtype C speciﬁc primers and probe.
Primer/Probe Sequence (5’-3’) Genomic location*
TAT1FC GAA GAA GCG GAG ACA GCG A 5977-5996
TAT2FC GCA GTG AGG ATC ATC AAA ATC CTA
TAT CAA AGC A
6012-6045
REV C GGA TCT GTC TCT GTC TTG CTC TCC 8436-8459
TILDA C [6FAM] CTT CTT CTT CGA TTC TTC CGA
GCC TGT CGG GT [TAM]
8402-8433
* Relative to the sequence of HXB2 reference strain of HIV-1.
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PCR Kit (Life Technologies) as previously described (Procopio et al.,
2015) and was run in a GeneAmp PCR system 9700 instrument (Ap-
plied Biosystem). Pre-ampliﬁcation was carried out with primers
TAT1FC and REVC (ﬁnal concentration of 0.25 μM each). At the end of
the pre-ampliﬁcation run, PCR products were diluted in 40 μl of water.
The subsequent real-time PCR was performed on the same day using
PrecisionPLUS qPCR Master Mix (PrimerDesign). 10 μl of 2X buﬀer
were added together with primers TAT2FC and REVC (ﬁnal con-
centration of 0.25 μM each), the probe TILDA C (ﬁnal concentration of
0.1 μM), 1 μl of pre-ampliﬁcation product and H2O to a ﬁnal volume of
20 μl. The real-time reaction was carried out in a VERSANT kPCR
Molecular System (Stratagene) using the following program: 5 min at
95 °C followed by 45 cycles of 95 °C 10 s and 60 °C for 60 s and ac-
quisition of the ﬂuorescent signal at the end of each cycle. The fre-
quency of cells expressing inducible msRNA of tat/rev was calculated as
described by Procopio and colleagues with the maximum likelihood
method (Procopio et al., 2015).
Each run included a calibration curve to control for the accuracy of
the PCR method. The curve was prepared using dilutions of the se-
quence of tat/rev msRNA of subtype C (gBlocks Gene Fragment, IDT)
which was ligated in a pGEM-T Easy vector (Promega) using a T4 ligase
(T4 DNA Ligase, Promega) and subsequently cloned into competent
bacterial cells. The TILDA plasmid obtained (pTatRevC) was isolated
with High Pure Plasmid Isolation Kit (Roche) and stored at -20 °C. The
plasmid was diluted to obtain the following calibration scale: 5 × 104
copies/reaction, 5 × 103 copies/reaction, 5 × 102 copies/reaction, 5
× 101 copies/reaction, and 5 × 100 copies/reaction. Each plasmid
dilution was tested in duplicate.
2.5. Evaluation of cross-reactivity between subtype B and C assays
CD4+ T cells obtained from patients infected with HIV-1 subtype B
or C were stimulated according to the protocol described in section 2.3.
RNA was extracted using the Hybrid-R miRNA (GeneAll) following
manufacturer’s instruction and eluted in 50 μl. Pre-ampliﬁcation was
carried out using SuperScript III Platinum One-Step qRT-PCR Kit (Life
Technologies) starting from 1 μl of RNA. Pre-ampliﬁcation and the real-
time PCR subsequent steps were performed as described in section 2.4.
Each patient sample was run in quadruplicate and tested both with
subtype B primers and probe and subtype C primers and probe.
2.6. Statistical analysis
Statistical analyses were carried out using Graphpad Prism 5 soft-
ware. Pearson test (two-tailed) was used to analyze data and a p<0.05
was considered as the level of signiﬁcance.
3. Results
3.1. Optimization of TILDA for the detection of C-subtype tat/rev
The signiﬁcant increase in prevalence of non-B subtypes in Europe
and Noth America, suggests that the molecular epidemiology of HIV-1
is changing (Lai et al., 2014; Mazzuti et al., 2019). Here we modiﬁed
the published protocol for TILDA (Procopio et al., 2015) to detect
subtype C viruses and be able to quantify reservoir in long-term subtype
C HIV-1 infected patients, who constitute a growing population among
HIV-1 infected patients.
First, we designed a new set of primers and probe based on the
consensus subtype C HIV-1 sequence available on the Los Alamos HIV
database. In order to enhance the sensitivity of the primers, we aligned
and compared 382 sequences, identifying the regions carrying the
lower variation rate and, where variation was not avoidable, selecting
the most conserved nucleotides (Fig. 1).
Second, we changed the original dilution panel (18 × 106 cells/ml,
9 × 106 cells/ml, 3 × 106 cells/ml and 1 × 106 cells/ml) by
performing the following dilutions: 54 × 106 cells/ml, 27 × 106 cells/
ml, 9 × 106 cells/ml and 3 × 106 cells/ml. As a result, using the same
number of reactions, we tested a higher number of cells (7,44 × 105 vs
2,232 × 106). We evaluated the eﬀect of increasing the number of
cells/well in two patients, one infected with subtype B and the other
with subtype C: in both cases, we were able to quantify the reservoir
only using the modiﬁed dilution panel (Supplementary Table S1).
The sensitivity of the PCR method was assessed using serial dilu-
tions of a plasmid containing the target sequence. After extraction and
real-time RT-PCR, the assay sensitivity limit, deﬁned as the dilution
where 100 % of replicates was detectable at Ct values≤25, was set at 5
copies/reaction. The Ct values showed linear reference curves for
pTatRevC plasmid (Fig. 2, r2> 0.95). The inter-assay coeﬃcient of
variability of the Ct values ranged from 1.04 % to 1.25 %. The median
slope was –3.22 (range, -2.83 to -3.43) and the median eﬃciency was
106 % (range, 95.6%–125.8%).
We characterized the cross-reactivity between subtype B and sub-
type C primers and probe sets using RNA extracted from stimulated
CD4+ T cells obtained from six patients, three infected with HIV-1
subtype B and three with HIV-1 subtype C. In all samples, total RNA
was retrotranscribed and ampliﬁed following the TILDA RT-PCR
method using either subtype B or subtype C primers and probe. Only
subtype B primers and probe were able to amplify tat/rev msRNA in
samples obtained from subtype B infected patients. Similarly, RNA
extracted from HIV-1 subtype C samples was successfully ampliﬁed
with subtype C primers and probe, while no signal was detected using
subtype B primers and probe (Supplementary Table S2).
Finally, when we performed the assays on cells derived from a
subtype C infected patient, we were able to detect msRNA and quantify
viral reservoir only using the C-TILDA (Table 2, row 3). Interestingly,
we could not detect any signal with subtype B TILDA even when in-
creasing the number of replicates to reach 4 million cells total (data not
shown), further supporting the absence of cross-reactivity between as-
says.
3.2. C-TILDA eﬀectively quantiﬁes reservoir in C infected patients
To conﬁrm the performances of C-TILDA, we performed the assay
on samples derived from routine clinical practice, which are more likely
to reﬂect the real-life heterogeneity of the HIV-1 population. We iso-
lated CD4+ T cells from 12 patients, three infected with a subtype B
virus and nine infected with subtype C. At the time of collection, plasma
viral (RNA) load was determined for all patients to conﬁrm viral sup-
pression. Table 2 shows the frequency of CD4+ T cells expressing tat/
rev msRNA detected by TILDA using the original assay developed by
Procopio and colleagues (Procopio et al., 2015), for subtype B samples,
and the newly developed C-TILDA assay, for subtype C samples. As
expected, the original assay successfully quantiﬁed the cells producing
msRNA in subtype B infected patients. On the other hand, the C-TILDA
was able to detect the target in eight out of nine tested subtype C in-
fected patients, with the number of infected cells per million CD4+ T
cells ranging from 1 to 24 (Table 2). Consistent with the high level of
viral suppression in the patients selected to test the assay, in whom
viremia had been below the limit of detection for at least one year, we
detected a median frequency of tat/rev msRNA producing CD4+ T cells
of less than 10 per million of CD4+ T cells. Our method was not able to
detect any tat/rev msRNA producing cell only in one patient who had
undetectable plasma viremia for more than three years (Table 3).
3.3. The number of CD4+T cells producing tat/rev msRNA correlates with
immunological and virological parameters
We performed an exploratory analysis to assess whether the results
of C-TILDA assay correlated with patient immunological and virological
parameters (Table 3). Patient 3 was excluded from the analysis due to
the lack of clinical and immunological information.
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We compared the results of the C-TILDA with the duration of viral
suppression and total HIV-1 DNA. Given that plasma viral RNA was
below the limit of quantiﬁcation in all patients included in the study,
we considered the time since reaching viral suppression as a surrogate
marker of viral control. Consistent with a role of suppressive cART in
promoting reservoir decay (Chun et al., 2007; Siliciano et al., 2003),
TILDA results signiﬁcantly correlated with the time since virological
suppression (Fig. 3A, r2 = 0.505, p = 0.048).
Similarly, HIV-1 DNA is frequently used as a biomarker of the viral
reservoir since it has a slower decay than plasma HIV-1 RNA, whose
levels can be reduced below the limit of detection of clinical assays
within a few months after cART initiation. Nevertheless, the biological
meaning of HIV-1 DNA in long-term virosuppressed patients is still
debated, given that the vast majority of infected cells harbor defective
proviruses and thus are not targeted by antiviral therapy. In this study,
we observed a signiﬁcant positive correlation between the number of
cells harboring replication-competent virus estimated by C-TILDA (pa-
tients 5–11, Fig. 3B, r2 = 0.573 p = 0.049) and the amount of HIV-1
Fig. 1. Graphic representation of the target regions of subtype C-speciﬁc primers and probe set. The height of each nucleotide is proportional to the degree of
conservation of the nucleotide among subtype C sequences available in Los Alamos HIV database. The red squares highlight the sequence of C-TILDA primers A)
TAT1FC, B) TAT2FC, C) REV C and D) TILDA C probe (for interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article).
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DNA within the CD4+ T cell population.
Importantly, we found that C-TILDA results signiﬁcantly correlated
with the CD4/CD8 ratio, a key parameter reﬂecting the functionality of
the immune system (Fig. 3C, r2 = 0.504 p = 0.049), supporting the
notion that recovery of immune system function is linked to the re-
duction of reservoir size.
4. Discussion
The presence of latently infected cells precludes viral eradication in
patients receiving cART (Archin et al., 2012; Siliciano et al., 2003).
Hence, reaching a better understanding of viral dynamics during
chronic infection is critical in order to properly understand the eﬃcacy
of available regimens against cellular reservoirs and establish the
Fig. 2. Standard curve of pTatRevC using the set of primers and probe speciﬁc
for subtype C HIV-1. Boxes show median and interquartile ranges of Ct values
obtained from three diﬀerent runs performed in duplicate.
Table 2
Evaluation of the reservoir size by TILDA in long-term cART treated patients
(conﬁdence interval 95 %). TND: target not detected. NA: not analyzed.
B-TILDA C- TILDA
Patient Subtype Cells
expressing
tat/rev
msRNA/106
CD4+ T cells
Conﬁdence
Interval (95
%)
Cells
expressing
tat/rev
msRNA/106
CD4+ T cells
Conﬁdence
Interval (95
%)
1 B 12 8-17 NA
2 B 3 1-6 NA
3 C TND TND 24 17-33
4 B 136 93-197 NA
5 C NA 7 4-12
6 C NA 1 0-4
7 C NA 14 8-25
8 C NA 16 7-35
9 C NA 7 4-14
10 C NA 6 2-14
11 C NA 11 3-37
12 C NA 0 0
Table 3
Clinical data of patients infected with subtype C. NA: not analyzed.
Patient Time since diagnosis
(years)
Time since virological suppression
(months)
CD4+T cells/μl CD4/CD8
ratio
Total HIV-DNA (copies/106
CD4+T cells)
tat/rev msRNA+ CD4+T cells/106
CD4+T cells
5 3 24 2025 1.19 190 7
6 5 54 1484 1.50 226 1
7 2 25 739 0.43 1521 14
8 2 24 287 0.21 1236 16
9 2 24 1041 0.47 765 7
10 2 24 1044 0.74 95 6
11 5 12 386 0.13 1530 11
12 5 41 645 0.70 NA 0
Fig. 3. Association between the reservoir size measured by TILDA and A) time
from virological suppression (r2 = 0.505; p = 0.048); B) HIV-1 DNA proviral
load (r2 = 0.573, p = 0.049), due to insuﬃcient material, patient 12 was not
tested for total HIV-1 DNA; and C) current CD4/CD8 ratio (r2 = 0.504, p =
0.049). Statistical analysis was performed using Pearson test (two-tailed), and
setting 0.05 as the level for signiﬁcance.
A. Bertoldi, et al. Journal of Virological Methods 276 (2020) 113778
5
optimal clinical and therapeutic strategies for patient management. In
patients on prolonged suppressive cART, it is estimated that the fre-
quency of latently infected cells within the resting memory CD4 + T
population, which is considered the more relevant compartment for
latency, is 1 in 106 cells (Eriksson et al., 2013; Ho et al., 2013).
Quantiﬁcation of HIV-1 reservoir remains challenging: several
techniques targeting diﬀerent viral targets have been proposed to assess
its size, with variable degrees of concordance (Ho et al., 2013; Sharaf
and Li, 2017). TILDA is a PCR-based method that quantiﬁes the re-
servoir size based on the ability of the reactivated CD4+ T cells to
produce tat/rev msRNA. In this study, we modiﬁed the original pro-
tocol allowing the successful quantiﬁcation of the viral reservoir in
long-term cART treated patients infected with subtype C virus.
As suggested by Procopio (Procopio et al., 2015), TILDA assay may
not detect tat/rev msRNA in patients infected with HIV-1 non-B sub-
types. Consistently, in our hands, the assay could not detect tat/rev
msRNA in samples from patients infected with clade C virus.
The implementation of the assay for HIV-1 subtype C detection of-
fers the chance of further evaluating the reservoir size in subtype C
infected patients. The high prevalence of HIV-1 subtype C in the
southern African countries along with India and Ethiopia, where it is
involved in more than 94 % of HIV-1 infections, as well as the in-
creasing migratory ﬂows are fueling subtype C global expansion.
Currently, HIV-1 subtype C represents 46.6 % of the infections world-
wide and its frequency in western and central Europe and North
America is around 4 % (Hemelaar et al., 2019). Therefore, the devel-
opment of tools that can quantify subtype C virus is pivotal for the
advent of new strategies aiming at curing HIV-1 infection.
Although QVOA currently represents the gold standard for reservoir
quantiﬁcation, TILDA has the advantage of requiring a consistently
lower amount of blood and being less time-consuming compared to
QVOA that requires from 7 to 21 days (Wang et al., 2018).
Currently, most of the clade C virus analyses are PCR-based and can
involve ddPCR (Bosman et al., 2018) or NGS (Rodgers et al., 2017),
although the use of RNAscope ISH technique has been recently reported
(Zhang et al., 2018). Despite overestimating its true size (Sharaf and Li,
2017), HIV-1 DNA is one of the most common markers used to assess
the viral reservoir. Several studies highlighted the importance of
choosing the proper PCR-based assay to guarantee an optimal mea-
surement of HIV-1 DNA, regardless of the subtype (Bosman et al., 2018;
Rutsaert et al., 2018). Viral diversity can limit DNA quantiﬁcation to a
variable extent, depending on the target region of the diﬀerent assays.
Bosman and colleagues observed that LTR (Aitken et al., 2013) and JO
(pol) assays (Benki et al., 2006; Pankau et al., 2018; Rousseau et al.,
2004) can sensitively and reliably measure HIV-1 DNA, whereas Gag
assay (Bosman et al., 2015) can detect only speciﬁc subtypes (Bosman
et al., 2018; Thomas et al., 2019).
A new method combines single-cell sorting and ddPCR enabling
high-throughput characterization of a speciﬁc cell population infected
with the virus. This new technique has been employed both for HIV-1
DNA analysis and unspliced and multiple spliced HIV-1 RNA quantiﬁ-
cation (Araínga et al., 2017; Dunay et al., 2017; Gibellini et al., 2018;
Morón-López et al., 2017; Yucha et al., 2017). Nevertheless, the pos-
sibility that changes in the viral sequence may inﬂuence the sensitivity
of the assay has not been explored yet.
In this complex scenario, we focused on TILDA assay as it combines
the accuracy in detecting cells harboring replication-competent virus
with limited technical complexity and the possibility to scale up for
high throughput testing.
Notwithstanding the advantages oﬀered by TILDA, the assay still
oﬀers room for improvement. In a recent publication, Pezzi and col-
leagues (Pezzi et al., 2018) proposed to increase TILDA sensitivity using
a bead-based method for RNA extraction to remove background cell-
derived material. Moreover, the production of msRNA is associated
with cell vitality and, therefore, correct handling and rapid processing
of the sample before and after stimulation are pivotal for the accuracy
of the assay. Hence, as suggested by Chatel and colleagues, we avoided
the storage of the pre-ampliﬁcation product at – 20 °C to prevent the
loss of sensitivity of TILDA (Châtel et al., 2018).
We designed a new set of primers and probe to recognize tat/rev
msRNA of clade C viruses, enabling the detection of the target in pa-
tients infected with subtype C viruses. Furthermore, we focused on the
analysis of viral reservoir in long-term virosuppressed patients that are
considered promising candidates for structured treatment interruption.
In these patients, the frequency of latently infected cells is very low
(Buzon et al., 2014), and thus, using the published TILDA protocol, it
would be necessary to increase the number of wells tested in each run.
We instead increased the number of CD4+ T cells per well, thereby
incrementing the likelihood of ﬁnding latently infected cells without
impacting the cost of the assay. Although, in our hands, the new dilu-
tion panel allowed to detect HIV-1 msRNA in two samples that tested
negative using the original dilution set, we are aware that increasing
the number of cells per well could increase the background and reduce
the sensitivity (Châtel et al., 2018). It is worth noting, however, that
three out of four of the cell dilutions used in our experimental setting (3
× 106 cells/ml, 9 × 106 cells/ml, and 27 × 106 cells/ml) fall within
the range of concentrations that did not signiﬁcantly impact ampliﬁ-
cation in the experiments performed by Chatel et al. Furthermore, the
observations reported by Chatel and colleagues have been obtained in a
diﬀerent experimental setting, where RNA extracted of ACH-2 cells is
added to either monocytes or CD4+ T cells. In these conditions, the
decrease in sensitivity may be due to not only to reaction inhibition but
also to RNAse activity on free RNA.
The size of the latent reservoir was measurable in eight out of the
nine subtype C infected patients included in the analysis, with only one
patient remaining undetectable possibly due to the long period of viral
suppression (41 months). Although primers and probes were designed
in the regions with the lowest sequence variation, it is not possible to
exclude that mismatches prevented ampliﬁcation in this patient.
Indeed, suboptimal detection due to sequence variability is common in
HIV-1 molecular assays and has been reported also for diagnostic tools
(Rouet et al., 2007). Furthermore, although the virus was identiﬁed as
subtype C based on pol gene sequence, recombination may occur among
diﬀerent subtypes, generating chimeric viruses which represent a fur-
ther challenge for diagnostic methods (Ramirez et al., 2008). Future
studies, performed on larger cohorts of patients will allow us to esti-
mate precisely the proportion of subtype C viruses which may escape
detection with C-TILDA.
In long-term suppressed patients infected with subtype C, the fre-
quency of CD4+ T cells expressing tat/rev msRNA ranged from 1 to 24
per million CD4+ T cells. Our data are in line with a recently published
work where reservoir size was determined using HIV-Flow, a ﬂow cy-
tometry-based assay to quantify p24+ cells (Pardons et al., 2019), and
compared with the results of other assays assessing the size of the latent
reservoir, including TILDA. Using TILDA, the authors reported a median
of 20.1 tat/rev msRNA+ CD4+T cells/106 cells, while the frequency of
p24 producing cells, as assessed by HIV-ﬂow, was 4.3/106 cells
(Pardons et al., 2019). Moreover, they showed a signiﬁcant correlation
between HIV-Flow and TILDA assay. Hence, TILDA could be a solid
alternative option when the starting material does not have a suﬃcient
number of cells, considering that HIV-Flow requires at least 5 × 106
CD4+ T cells (Pardons et al., 2019).
The fate of the viral reservoir under suppressive therapy is still
debated. Although several authors suggested that eﬀective anti-
retroviral therapy leads to a progressive decay of the reservoir (Chun
et al., 2007; Siliciano et al., 2003), recent works have questioned this
view, showing that despite a rapid decline during the ﬁrst months after
starting cART, viral reservoir remains stable (Crooks et al., 2015;
Honeycutt et al., 2017; Nikolaus et al., 2018) and that intensiﬁcation of
antiretroviral regimens does not signiﬁcantly inﬂuence residual viremia
(Gandhi et al., 2010). Our exploratory analysis highlighted a correla-
tion between TILDA results and time of viral suppression, supporting a
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role of suppressive cART in promoting reservoir decline. These data,
however, need to be conﬁrmed in longitudinal studies in which patients
will be followed over time since starting of therapy. In this scenario, the
TILDA might provide a better estimate of the viral reservoir than pro-
viral DNA. Here we showed a signiﬁcant correlation between reservoir
size assessed by TILDA and total HIV-1 DNA in CD4+ T cells, similarly
to what previously observed by Procopio (Procopio et al., 2015) in
subtype B viruses. Interestingly, although both methods may over-
estimate the size of the reservoirs, TILDA it is likely to be more accurate
because of the lower chances to observe tat/rev msRNA production
from defective viruses. Consistently, Pardons et al. recently reported
that the prediction of reservoir size obtained with TILDA is 50 times
more accurate than the one based on HIV-DNA (Pardons et al., 2019).
Finally, among the patients included in the analysis, the size of the
reservoir assessed by TILDA correlated with the CD4/CD8 ratio, a
known marker of immune recovery (Han et al., 2018; Mussini et al.,
2015). Although obtained on a limited number of samples, these results
further support the accuracy and clinical meaning of the assay.
In conclusion, we report the successful implementation of C-TILDA
to detect tat/rev transcripts of subtype C HIV-1, emphasizing the clin-
ical relevance of adapting molecular assays to the changing epide-
miology of the virus and the need to make available the most advanced
molecular assays to the entire HIV-1 positive population. This is es-
sential to drive forward cure research and comply with the UN aim to
end the HIV epidemic by 2030. Future challenges may involve the
implementation of this attractive technique extending its application to
additional non-B subtypes.
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